A practical look at where remote and hybrid approaches can improve medical device trials—and where direct clinical oversight still matters.
Decentralized clinical trials have become one of the most discussed shifts in clinical research over recent years.
In medtech, the promise is compelling: broader patient access, reduced site burden, faster recruitment, and more flexible participation models.
And in some settings, those benefits are very real.
But for medical devices, the conversation is often more complex than the headlines suggest.
Unlike many pharmaceutical studies, device trials frequently depend on procedural interventions, hands-on training, imaging, technical assessments, and ongoing investigator oversight.
That changes what “decentralized” can realistically mean.
In practice, very few device studies are fully decentralized. Most operate somewhere along a spectrum between traditional site-based models and selectively remote components.
That distinction matters.
The challenge is not whether decentralized approaches should be used. It is whether they are being applied in ways that genuinely improve study quality and patient participation — rather than simply following industry momentum.
Some trial activities transition well to remote models. Others become operationally fragile when moved too far from the clinical environment.
The strongest programs tend to approach this pragmatically.
They evaluate decentralization at the level of the individual study requirement: What improves accessibility? What maintains data integrity? What still requires direct clinical oversight?
That often leads to hybrid models rather than fully virtual ones.
As regulatory expectations around device evidence continue to evolve, this balance becomes increasingly important.
Decentralization can absolutely strengthen device trials when implemented deliberately. But in many cases, the real opportunity is not replacing traditional trial models entirely — it is selectively redesigning parts of them more intelligently.
That is a very different conversation from simply asking whether decentralized trials are the future.